Company Hansa Biopharma AB Nasdaq Stockholm
Equities
SE0002148817
Biotechnology & Medical Research
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody-cleaving Enzyme Technology Platform
100.0
%
| 155 | 100.0 % | 134 | 100.0 % | -13.22% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe (excluding Sweden)
79.6
%
| 86 | 55.4 % | 107 | 79.6 % | +24.66% |
North America
20.4
%
| 64 | 41.6 % | 27 | 20.4 % | -57.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 20/18/20 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/12 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 29/20/29 |
- | - | ||
Klaus Sindahl
IRC | Investor Relations Contact | - | 29/19/29 |
Matthew Shaulis
PRN | Corporate Officer/Principal | - | 16/23/16 |
Max Sakajja
PRN | Corporate Officer/Principal | 43 | 01/17/01 |
Anne Lanner
HRO | Human Resources Officer | 55 | 18/19/18 |
Vincenza Nigro
PRN | Corporate Officer/Principal | - | 17/18/17 |
Magnus Korsgren
PRN | Corporate Officer/Principal | 55 | 01/21/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 29/18/29 | |
Peter Nicklin
CHM | Chairman | 61 | 30/22/30 |
Mats Blom
BRD | Director/Board Member | 59 | 22/19/22 |
Eva Nilsagård
BRD | Director/Board Member | 60 | 22/19/22 |
Hilary Malone
BRD | Director/Board Member | 59 | 12/21/12 |
Andreas Eggert
BRD | Director/Board Member | 56 | 29/18/29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 2,362,445 | 0 | 2,362,445 ( 100.00 %) | 88.64 % |
Stock B | 1 | 52,443,962 | 48,580,000 ( 92.63 %) | 0 |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
HANSA BIOPHARMA AB 100.00% | 2,598,012 | 100.00% | 7,070,516 $ |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |